Circulating Apelin is increased in patients with type 1 or type 2 diabetes and is associated with better glycaemic control

Clinical Endocrinology

Volumn 81, Issue 5, 2014, Pages 696-701

  Habchi, Marana ^a   Duvillard, Laurence ^b   Cottet, Vanessa ^b   Brindisi, Marie Claude ^a,b   Bouillet, Benjamin ^a,b   Beacco, Maud ^a   Crevisy, Elodie ^a   Buffier, Perrine ^a   Baillot Rudoni, Sabine ^a   Verges, Bruno ^a,b   Petit, Jean Michel ^a,b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN; GLYCOSYLATED HEMOGLOBIN; APLN PROTEIN, HUMAN; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; AGED; BLOOD; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; UPREGULATION;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; UP-REGULATION;

EID: 84912009719     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12404     Document Type: Article

References (30)

1. Tatemoto, K., Hosoya, M., Habata, Y., et al,. (1998) Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochemical and Biophysical Research Communications, 251, 471-476.
2. Lee, D.K., Cheng, R., Nguyen, T., et al,. (2000) Characterization of apelin, the ligand for the APJ receptor. Journal of Neurochemistry, 74, 34-41.
3. Masri, B., Knibiehler, B., &, Audigier, Y., (2005) Apelin signalling: a promising pathway from cloning to pharmacology. Cellular Signalling, 17, 415-426.
4. Habata, Y., Fujii, R., Hosoya, M., et al,. (1999) Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochimica et Biophysica Acta, 1452, 25-35.
5. O'Carroll, A.M., Selby, T.L., Palkovits, M., et al,. (2000) Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochimica et Biophysica Acta, 1492, 72-80.
6. Wang, G., Anini, Y., Wei, W., et al,. (2004) Apelin, a new enteric peptide: localization in the gastrointestinal tract, ontogeny, and stimulation of gastric cell proliferation and of cholecystokinin secretion. Endocrinology, 145, 1342-1348.
7. Medhurst, A.D., Jennings, C.A., Robbins, M.J., et al,. (2003) Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. Journal of Neurochemistry, 84, 1162-1172.
8. Boucher, J., Masri, B., Daviaud, D., et al,. (2005) Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology, 146, 1764-1771.
9. Tatemoto, K., Takayama, K., Zou, M.X., et al,. (2001) The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regulatory Peptides, 99, 87-92.
10. Szokodi, I., Tavi, P., Földes, G., et al,. (2002) Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circulation Research, 91, 434-440.
11. Taheri, S., Murphy, K., Cohen, M., et al,. (2002) The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochemical and Biophysical Research Communications, 291, 1208-1212.
12. Valle, A., Hoggard, N., Adams, A.C., et al,. (2008) Chronic central administration of apelin-13 over 10 days increases food intake, body weight, locomotor activity and body temperature in C57BL/6 mice. Journal of Neuroendocrinology, 20, 79-84.
13. O'Shea, M., Hansen, M.J., Tatemoto, K., et al,. (2003) Inhibitory effect of apelin-12 on nocturnal food intake in the rat. Nutritional Neuroscience, 6, 163-167.
14. Sunter, D., Hewson, A.K., &, Dickson, S.L., (2003) Intracerebroventricular injection of apelin-13 reduces food intake in the rat. Neuroscience Letters, 353, 1-4.
15. Clarke, K.J., Whitaker, K.W., &, Reyes, T.M., (2009) Diminished metabolic responses to centrally-administered apelin-13 in diet-induced obese rats fed a high-fat diet. Journal of Neuroendocrinology, 21, 83-89.
16. Dray, C., Knauf, C., Daviaud, D., et al,. (2008) Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metabolism, 8, 437-445.
17. Yue, P., Jin, H., Aillaud, M., et al,. (2010) Apelin is necessary for the maintenance of insulin sensitivity. American Journal of Physiology-Endocrinology and metabolism, 298, E59-E67.
18. Li, L., Yang, G., Li, Q., et al,. (2006) Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Experimental and Clinical Endocrinology & Diabetes, 114, 544-548.
19. Soriguer, F., Garrido-Sanchez, L., Garcia-Serrano, S., et al,. (2009) Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obesity Surgery, 19, 1574-1580.
20. Dray, C., Debard, C., Jager, J., et al,. (2010) Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. American Journal of Physiology-Endocrinology and metabolism, 298, E1161-E1169.
21. Erdem, G., Dogru, T., Tasci, I., et al,. (2008) Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes, 116, 289-292.
22. Zhang, Y., Shen, C., Li, X., et al,. (2009) Low plasma apelin in newly diagnosed type 2 diabetes in Chinese people. Diabetes Care, 32, e150.
23. Meral, C., Tascilar, E., Karademir, F., et al,. (2010) Elevated plasma levels of apelin in children with type 1 diabetes mellitus. Journal of Pediatric Endocrinology & Metabolism, 23, 497-502.
24. Alexiadou, K., Kokkinos, A., Liatis, S., et al,. (2012) Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration. Hormones (Athens, Greece), 11, 444-450.
25. Cavallo, M.G., Sentinelli, F., Barchetta, I., et al,. (2012) Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus. PLoS ONE, 7, e51236.
26. Reinehr, T., Woelfle, J., &, Roth, C.L., (2011) Lack of association between apelin, insulin resistance, cardiovascular risk factors, and obesity in children: a longitudinal analysis. Metabolism, 60, 1349-1354.
27. Heinonen, M.V., Purhonen, A.K., Miettinen, P., et al,. (2005) Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regulatory Peptides, 130, 7-13.
28. Kadoglou, N.P.E., Tsanikidis, H., Kapelouzou, A., et al,. (2010) Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism, 59, 373-379.
29. Kadoglou, N.P.E., Sailer, N., Kapelouzou, A., et al,. (2012) Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Acta Diabetologica, 49, 269-276.
30. Castan-Laurell, I., Dray, C., Knauf, C., et al,. (2012) Apelin a promising target for type 2 diabetes treatment? Trends in Endocrinology and Metabolism: TEM, 23, 234-241.